Cargando…
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review
Blau syndrome (BS) is an autoinflammatory disorder characterized by non-caseating granulomatous dermatitis, arthritis, and uveitis. We present a case of refractory and severe BS that was treated with the Janus kinase inhibitors (JAKINIBS), Tofacitinib (TOFA) and then Baricitinib (BARI). Our aim was...
Autores principales: | Álvarez-Reguera, Carmen, Prieto-Peña, Diana, Herrero-Morant, Alba, Sánchez-Bilbao, Lara, Martín-Varillas, José Luis, González-López, Elena, Gutiérrez-Larrañaga, María, San Segundo, David, Demetrio-Pablo, Rosalía, Ocejo-Vinyals, Gonzalo, González-Gay, Miguel A., Blanco, Ricardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058350/ https://www.ncbi.nlm.nih.gov/pubmed/35510170 http://dx.doi.org/10.1177/1759720X221093211 |
Ejemplares similares
-
Baricitinib in severe and refractory peripheral ulcerative keratitis:
a case report and literature review
por: Calvo-Río, Vanesa, et al.
Publicado: (2022) -
Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life
por: Deprez, Valentine, et al.
Publicado: (2020) -
Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients
por: Zhang, Song, et al.
Publicado: (2021) -
Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome
por: Ueki, Yoko, et al.
Publicado: (2023) -
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2021)